This is a multi-centre, multi-drug, platform study in Chinese participants living with obesity/overweight

Exclusion Criteria

• 1.Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening.
• 2.History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control.
• 3.Treatment with diabetes medication in past 3 months prior to screening.
• 4.HbA1c ≥ 6.5% (48 mmol/mol) at screening.
• 5.Gastroparesis (or similar) requiring treatment.
• 6.Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract.
• 7.Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:
• (a) AST ≥ 2.5 × ULN
• (b) ALT ≥ 2.5 × ULN
• (c) TBL ≥ 1.5 × ULN.
• 8.Prior history of cholecystectomy or untreated cholelithiasis.
• 9.History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULN at screening.
• 10.Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes.
• 11.HR < 50 bpm or > 100 bpm after being at rest for 5 minutes.
• 12.Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI).
• 13.History of psychosis or bipolar disorder.
• 14.Severe vitamin D deficiency defined as a 25-OH vitamin D level < 12 ng/mL.
• 15.Uncontrolled thyroid disease, defined as TSH > ULN or < LLN for the laboratory reference range, as judged by the PI at screening.